Stockscreener 앱 받기
1.31
4.38%
-0.06
전일 마감가:
$1.37
열려 있는:
$1.36
하루 거래량:
1.66M
Relative Volume:
0.67
시가총액:
$547.40M
수익:
$1.21M
순이익/손실:
$-177.12M
주가수익비율:
-1.6375
EPS:
-0.8
순현금흐름:
$-162.37M
1주 성능:
+11.02%
1개월 성능:
+11.02%
6개월 성능:
+23.58%
1년 성능:
+88.49%
1일 변동 폭
$1.29
$1.37
1주일 범위
$1.17
$1.385
52주 변동 폭
$0.2836
$1.83
렉시콘 파마슈티컬스 Stock (LXRX) Company Profile
명칭
Lexicon Pharmaceuticals Inc
전화
(281) 863-3000
주소
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.31 | 572.48M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
렉시콘 파마슈티컬스 Stock (LXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | 개시 | H.C. Wainwright | Buy |
| 2024-04-30 | 개시 | Leerink Partners | Outperform |
| 2023-03-07 | 개시 | Jefferies | Hold |
| 2022-08-12 | 개시 | Piper Sandler | Overweight |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-01-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-18 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-12-11 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-09-11 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-07-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-03-25 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2018-07-31 | 재확인 | Stifel | Buy |
| 2018-02-23 | 다운그레이드 | Needham | Buy → Hold |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-03-01 | 재확인 | H.C. Wainwright | Buy |
| 2017-03-01 | 재확인 | Wedbush | Outperform |
| 2016-10-07 | 개시 | H.C. Wainwright | Buy |
| 2016-08-05 | 재확인 | Wedbush | Outperform |
| 2016-08-02 | 개시 | Citigroup | Buy |
| 2016-03-02 | 재확인 | Wedbush | Outperform |
| 2015-11-09 | 재확인 | Wedbush | Outperform |
| 2015-09-28 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2015-09-18 | 다운그레이드 | Gabelli & Co | Hold → Sell |
| 2015-08-10 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
렉시콘 파마슈티컬스 주식(LXRX)의 최신 뉴스
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
Sentiment Recap: Does Lexicon Pharmaceuticals Inc meet Warren Buffetts criteriaTrade Risk Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Lexicon Pharmaceuticals completes $100 million stock offering By Investing.com - Investing.com Nigeria
Lexicon Pharmaceuticals completes $100 million stock offering - Investing.com
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - The Manila Times
Lexicon Pharmaceuticals Completes Public Offering of Common Stock and Concurrent Private Placement - Quiver Quantitative
Lexicon raises about $94.6M to fund drug work and operations - Stock Titan
Lexicon Pharmaceuticals prices $94.6M share offering - MSN
Insider Buying: Lexicon Pharmaceuticals (NASDAQ:LXRX) Director Acquires 1,538,462 Shares of Stock - MarketBeat
Market Review: How does Lexicon Pharmaceuticals Inc compare to its peersWeekly Market Outlook & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Lexicon Pharmaceuticals Bolsters Capital Through Equity Financing - The Globe and Mail
Lexicon Pharmaceuticals Signs Multiple Material Agreements - TradingView
FOMO Trade: Does Lexicon Pharmaceuticals Inc meet Warren Buffetts criteria2025 Momentum Check & Capital Protection Trade Alerts - baoquankhu1.vn
Lexicon Pharmaceuticals Initiates Stock Offering to Drive R&D Growth - StocksToTrade
Lexicon Pharmaceuticals Stock Offering: Strategic Move to Boost R&D - timothysykes.com
Pullback Watch: Can Lexicon Pharmaceuticals Inc reach all time highs this yearWeekly Trading Summary & Technical Pattern Alert System - baoquankhu1.vn
Lexicon Pharmaceuticals Announces Key Stock Offering amid Strategic Funding Efforts - StocksToTrade
Lexicon Pharmaceuticals prices public offering at $1.30 per share By Investing.com - Investing.com Nigeria
Lexicon Pharmaceuticals launches public offering of common stock By Investing.com - Investing.com Australia
Citi Raises Lexicon Pharmaceuticals (LXRX) Outlook on Strength of Novo Nordisk Partnership Milestones - Finviz
Lexicon Pharmaceuticals stock tumbles on public offering pricing By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals (LXRX) Engages Jefferies and Piper Sandl - GuruFocus
Lexicon Pharmaceuticals stock tumbles on public offering pricing - Investing.com India
Lexicon Pharmaceuticals (LXRX) Raises $41.6M Through Public Offe - GuruFocus
Lexicon Pharmaceuticals prices public offering at $1.30 per share - Investing.com
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - The Manila Times
Lexicon announces pricing of approximately $94.6 million public offering at $1.30 per share - marketscreener.com
Drug developer Lexicon raises $94.6M to fund pipeline and operations - stocktitan.net
Lexicon Pharmaceuticals (LXRX) Initiates Public Stock Offering - GuruFocus
Lexicon Pharmaceuticals (LXRX) Launches Public Offering, Shares Dip - GuruFocus
Lexicon Pharmaceuticals launches public offering of common stock - Investing.com
Lexicon Announces Proposed Public Offering of Common Stock - The Manila Times
Lexicon (NASDAQ: LXRX) plans stock sale, highlights late-stage pipeline - stocktitan.net
Lexicon plans stock sale to fund drug candidate research, operations - Stock Titan
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Down 8.5%Should You Sell? - MarketBeat
Lexicon Pharmaceuticals Rings the Closing Bell - Nasdaq
How A Reset Price Target Is Reframing The Story For Lexicon Pharmaceuticals (LXRX) - Yahoo Finance
Risk Report: Can Lexicon Pharmaceuticals Inc reach all time highs this year - baoquankhu1.vn
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Lexicon Pharma spikes after FDA feedback on pain drug - MSN
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Shows High-Growth Momentum with Strong Technical and Fundamental Trends - ChartMill
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary - Yahoo Finance
Biopharma’s 30-year run: Lexicon to ring Nasdaq closing bell - Stock Titan
Downgrade Watch: How does Lexicon Pharmaceuticals Inc compare to its peersJuly 2025 Pullbacks & Safe Entry Trade Reports - baoquankhu1.vn
렉시콘 파마슈티컬스 (LXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):